Dr Reddy's gets exclusive right to distribute UCB's epilepsy drug in India

Briviact is approved as an adjunctive therapy for the treatment of partial-onset seizures in epilepsy patients who are 16 years of age and older

Dr Reddy's Laboratories Limited and Belgian bio-pharmaceutical company UCB announced on Monday that they have entered into a distribution and co-promotion agreement for Briviact, a brand of epilepsy drug Brivaracetam. The agreement grants Dr Reddy's the exclusive right to distribute Briviact in India.

"In our endeavour to make innovative medicines accessible to patients in India and we are excited to partner with UCB India for Briviact, a novel treatment for epilepsy that will make a difference to the lives of patients living with epilepsy," M V Ramana CEO, Branded Markets at Dr Reddy's said. 

The companies did not reveal the financial details